Actively Recruiting
Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Led by Fudan University · Updated on 2025-12-24
34
Participants Needed
1
Research Sites
120 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.
CONDITIONS
Official Title
Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years old or older
- Histologically or cytologically confirmed non-squamous NSCLC with documented EGFR uncommon mutations from a local laboratory, including at least one uncommon mutation (excluding EGFR 19del, L858R, T790M, Exon 20 insertions) or compound mutations involving uncommon EGFR mutations
- Predicted life expectancy of 12 weeks or more
- Measurable disease according to RECIST 1.1
You will not qualify if you...
- Previous systemic anti-tumor therapy
- History of malignant tumors within the past 2 years
- Any severe or poorly controlled systemic disease as judged by the investigator
- Active infections
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan university shanghai cancer center
Shanghai, China
Actively Recruiting
Research Team
J
Jialei Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here